MIKEL CROSS: Open Payments
NPI 1407127202 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,675 in 90 payments from 18 companies in 2025. Trend: 2023 $2,254 · 2024 $1,057 · 2025 $1,675
Food & beverage: $1,590Education: $85
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $489 |
| Janssen Biotech, Inc. | 14 | $241 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $210 |
| Lilly USA, LLC | 5 | $134 |
| Madrigal Pharmaceuticals | 4 | $116 |
| Enterra Medical, Inc. | 1 | $80 |
| GENZYME CORPORATION | 3 | $64 |
| Celltrion USA Inc. | 2 | $48 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| Aimmune Therapeutics, Inc. | 2 | $44 |
Products named: TREMFYA, RINVOQ, SKYRIZI, OMVOH, ENTYVIO, REZDIFFRA, DUPIXENT, LINZESS.
Industry payments across OK — which companies pay providers there.
